Law360, New York (March 29, 2005, 12:00 AM ET) -- Two generic makers have been cleared by the U.S. Food and Drug Administration to sell versions of Eli Lilly & Co.’s bestselling drug, Zyprexa if they prevail in a closely watched federal patent lawsuit.
The U.S. Food & Drug Administration gave the approval to Israel-based Teva Pharmaceutical Industries on Monday and to Pennsylvania-based Mylan Laboratories Inc. on Tuesday.
If a judge finds in favor of generics makers in their patent litigation with Lilly, they could begin to sell generic versions of Zyprexa immediately. However, an appeal...
Teva, Mylan Get FDA OK For Zyprexa Generic
To view the full article, take a free trial now.
